Efficacy observation on Shuxuetong Injection combined with intravenous thrombolysis in treatment of acute mild ischemic stroke
Objective To observe the efficacy of Shuxuetong Injection combined with intravenous thrombolysis in treatment of acute mild ischemic stroke(AMIS).Methods A total of 90 cases of AMIS were randomly divided into control group and treatment group,with 45 cases in each group.Control group was given intravenous thrombolysis,and treatment group was given Shuxuetong on the basis of control group.The short-term efficacy,the National Institutes of Health Stroke Scale(NIHSS)and the Rankin Revised Scale score(mRs)were compared on the 7th day of treatment,the plasma prothrombin time(PT),fibrinogen(FIB),hypersensitive C-reactive protein(hs-CRP)and central nervous system-specific protein(S-100β)levels were compared between the two groups,platelet count(PLT),mean platelet volume(MPV)and platelet distribution width(PDW)were measured,and the prognosis was assessed 90 days after treatment with mRs.Results After treatment,the effective rate of treatment group was significantly higher than that of control group(P＜0.05),the scores of NIHSS and mRs in both groups were significantly lower than those before treatment(P＜0.05),and were significantly lower in treatment group than those in control group(P＜0.05);the levels of PT in both groups were significantly higher than those before treatment(P＜0.05),while the levels of FIB,hs-CRP and S-100β were significantly lower,and the above indexes were significantly superior in treatment group to those in control group(P＜0.05);the PLT in both groups was higher than that before treatment,while the MPV and PDW were significantly lower,and the above indexes were significantly superior in treatment group to those in control group(P＜0.05);90 days after treatment,the good outcome rate in treatment group was significantly higher than that in control group(P＜0.05).Conclusion Shuxuetong Injection combined with intravenous thrombolysis can improve neurological function,alleviate brain dysfunction,restore the balance between coagulation and fibrinolytic systems,reduce the levels of hs-CRP and S-l00β,improve platelet parameters,and improve long-term prognosis in treatment of AMIS.
NETL
NSTL
万方数据
